Host immune responses to SARS coronavirus in humans

Molecular Biology of the SARS-Coronavirus

Volumn , Issue , 2010, Pages 259-278

  Li, Chris Ka Fai ^a   Xu, Xiaoning ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900123989     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-03683-5_16     Document Type: Chapter

References (131)

1. Anonymous (2004) The involvement of natural killer cells in the pathogenesis of severe acute respiratory syndrome. Am J Clin Pathol 121(4):507-511
2. Bisht H, Roberts A et al (2004) Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 101(17):6641-6646
3. Bosch BJ, van der Zee R et al (2003) The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol 77(16):8801-8811
4. Bosch BJ, Martina BE et al (2004) Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci USA 101(22):8455-8460
5. Buchholz UJ, Bukreyev A et al (2004) Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA 101(26):9804-9809
6. Bukreyev A, Lamirande EW et al (2004) Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363(9427):2122-2127
7. Callendret B, Lorin V et al (2007) Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS. Virology 363(2):288-302
8. Cameron MJ, Ran L et al (2007) Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol 81(16):8692-8706
9. Cao WC, Liu W et al (2007) Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med 357(11):1162-1163
10. Chan CM, Ma CW et al (2007) The SARS-Coronavirus membrane protein induces apoptosis through modulating the Akt survival pathway. Arch Biochem Biophys 459(2):197-207
11. Chen J, Subbarao K (2007) The immunobiology of SARS. Annu Rev Immunol 25:443-472
12. Chen JH, Chang YW et al (2004) Plasma proteome of severe acute respiratory syndrome analyzed by two-dimensional gel electrophoresis and mass spectrometry. Proc Natl Acad Sci USA 101(49):17039-17044
13. Chen H, Hou J et al (2005) Response of memory CD8+ T cells to severe acute respiratory syndrome (SARS) coronavirus in recovered SARS patients and healthy individuals. J Immunol 175(1):591-598
14. Chen RF, Chang JC et al (2006) Role of vascular cell adhesion molecules and leukocyte apoptosis in the lymphopenia and thrombocytopenia of patients with severe acute respiratory syndrome (SARS). Microbes Infect 8(1):122-127
15. Cheng Y, Wong R et al (2005) Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 24(1):44-46
16. Cheng VC, Lau SK et al (2007) Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 20(4):660-694
17. Cheung CY, Poon LL et al (2005) Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol 79(12):7819-7826
18. Chien JY, Hsueh PR et al (2006) Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. Respirology 11(6):715-722
19. Chu CM, Poon LL et al (2004) Initial viral load and the outcomes of SARS. CMAJ 171(11):1349-1352
20. Chua KB, Bellini WJ et al (2000) Nipah virus: a recently emergent deadly paramyxovirus. Science 288(5470):1432-1435
21. Cinatl J, Morgenstern B et al (2003) Treatment of SARS with human interferons. Lancet 362(9380):293-294
22. Devaraj SG, Wang N et al (2007) Regulation of IRF-3-dependent innate immunity by the papainlike protease domain of the severe acute respiratory syndrome coronavirus. J Biol Chem 282(44):32208-32221
23. Drosten C, Gunther S et al (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348(20):1967-1976
24. Du L, He Y et al (2008) Development of subunit vaccines against severe acute respiratory syndrome. Drugs Today 44(1):63-73
25. Fan YY, Huang ZT et al (2009) Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection. Arch Virol 154(7):1093-1099
26. Formenty P, Hatz C et al (1999) Human infection due to Ebola virus, subtype Cote d'Ivoire: clinical and biologic presentation. J Infect Dis 179(Suppl 1):S48-S53
27. Freundt EC, Yu L et al (2009) Molecular determinants for subcellular localization of the severe acute respiratory syndrome coronavirus open reading frame 3b protein. J Virol 83(13):6631-6640
28. Frieman M, Baric R (2008) Mechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation. Microbiol Mol Biol Rev 72(4):672-685
29. Glass WG, Subbarao K et al (2004) Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol 173(6):4030-4039
30. Greenough TC, Babcock GJ et al (2005) Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis 191(4):507-514
31. Gu J, Gong E et al (2005) Multiple organ infection and the pathogenesis of SARS. J Exp Med 202(3):415-424
32. Haagmans BL, Kuiken T et al (2004) Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 10(3):290-293
33. Hamming I, Timens W et al (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203(2):631-637
34. He Z, Zhao C et al (2005) Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis 9(6):323-330
35. He Y, Li J et al (2006) Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol 176(10):6085-6092
36. Ho MS, Chen WJ et al (2005) Neutralizing antibody response and SARS severity. Emerg Infect Dis 11(11):1730-1737
37. Hofmann H, Pohlmann S (2004) Cellular entry of the SARS coronavirus. Trends Microbiol 12(10):466-472
38. Hofmann H, Pyrc K et al (2005) Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci USA 102(22):7988-7993
39. Hogan RJ (2006) Are nonhuman primates good models for SARS? PLoS Med 3(9):e411; author reply e415
40. Hsueh PR, Huang LM et al (2004) Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect 10(12):1062-1066
41. Hu MC, Jones T et al (2007) Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice. Vaccine 25(34):6334-6340
42. Huang KJ, Su IJ et al (2005) An interferon-gamma-related cytokine storm in SARS patients. J Med Virol 75(2):185-194
43. Huang IC, Bosch BJ et al (2006) SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J Biol Chem 281(6):3198-3203
44. Imai Y, Kuba K et al (2005) Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436(7047):112-116
45. Imai Y, Kuba K et al (2008) Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133(2):235-249
46. Ip WK, Chan KH et al (2005) Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis 191(10):1697-1704
47. Jeffers SA, Tusell SM et al (2004) CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci USA 101(44):15748-15753
48. Jiang Y, Xu J et al (2005) Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med 171(8):850-857
49. Kam YW, Kien F et al (2007) Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine 25(4):729-740
50. Kielian M, Rey FA (2006) Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol 4(1):67-76
51. Kobinger GP, Figueredo JM et al (2007) Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. Vaccine 25(28):5220-5231
52. Kopecky-Bromberg SA, Martinez-Sobrido L et al (2006) 7a protein of severe acute respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 mitogen-activated protein kinase. J Virol 80(2):785-793
53. Krahling V, Stein DA et al (2009) Severe acute respiratory syndrome coronavirus triggers apoptosis via protein kinase R but is resistant to its antiviral activity. J Virol 83(5):2298-2309
54. Ksiazek TG, Erdman D et al (2003) A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348(20):1953-1966
55. Kuba K, Imai Y et al (2005) A crucial role of angiotensin converting enzyme 2(ACE2) in SARS coronavirus-induced lung injury. Nat Med 11(8):875-879
56. Lam CW, Chan MH et al (2004) Severe acute respiratory syndrome: clinical and laboratory manifestations. Clin Biochem Rev 25(2):121-132
57. Lau SK, Woo PC et al (2005) Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 102(39):14040-14045
58. Law HK, Cheung CY et al (2005a) Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood 106(7):2366-2374
59. Law PT, Wong CH et al (2005b) The 3a protein of severe acute respiratory syndrome-associated coronavirus induces apoptosis in Vero E6 cells. J Gen Virol 86(Pt 7):1921-1930
60. Lee N, Hui D et al (2003) A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348(20):1986-1994
61. Li W, Moore MJ et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426(6965):450-454
62. Li W, Shi Z et al (2005) Bats are natural reservoirs of SARS-like coronaviruses. Science 310(5748):676-679
63. Li CK, Wu H et al (2008) T cell responses to whole SARS coronavirus in humans. J Immunol 181(8):5490-5500
64. Libraty DH, O'Neil KM et al (2007) Human CD4(+) memory T-lymphocyte responses to SARS coronavirus infection. Virology 368(2):317-321
65. Lin M, Tseng HK et al (2003) Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet 4:9
66. Lin JT, Zhang JS et al (2007) Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther 12(7):1107-1113
67. Liu S, Xiao G et al (2004) Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363(9413):938-947
68. Liu W, Fontanet A et al (2006) Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis 193(6):792-795
69. Lu L, Manopo I et al (2004) Immunological characterization of the spike protein of the severe acute respiratory syndrome coronavirus. J Clin Microbiol 42(4):1570-1576
70. Lu JH, Guo ZM et al (2005) Preparation and development of equine hyperimmune globulin F (ab') 2 against severe acute respiratory syndrome coronavirus. Acta Pharmacol Sin 26(12):1479-1484
71. Marra MA, Jones SJ et al (2003) The genome sequence of the SARS-associated coronavirus. Science 300(5624):1399-1404
72. Martin JE, Louder MK et al (2008) A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 26(50):6338-6343
73. Mossel EC, Wang J et al (2008) SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells. Virology 372(1):127-135
74. Murray K, Selleck P et al (1995) A morbillivirus that caused fatal disease in horses and humans. Science 268(5207):94-97
75. Narayanan K, Huang C et al (2008) Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells. J Virol 82(9):4471-4479
76. National Research Project for SARS, Beijing Group (2004) The involvement of natural killer cells in the pathogenesis of severe acute respiratory syndrome
77. *0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome. J Infect Dis 190(3):515-518
78. Ng PC, Lam CW et al (2004b) Inflammatory cytokine profile in children with severe acute respiratory syndrome. Pediatrics 113(Pt 1):e7-e14
79. Nicholls JM, Poon LL et al (2003) Lung pathology of fatal severe acute respiratory syndrome. Lancet 361(9371):1773-1778
80. Nicholls JM, Butany J et al (2006) Time course and cellular localization of SARS-CoV nucleoprotein and RNA in lungs from fatal cases of SARS. PLoS Med 3(2):e27
81. Nie Y, Wang G et al (2004) Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J Infect Dis 190(6):1119-1126
82. Openshaw PJ, Culley FJ et al (2001) Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 20(Suppl 1):S27-S31
83. Peiris JS, Lai ST et al (2003) Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361(9366):1319-1325
84. Peng H, Yang LT et al (2006a) Human memory T cell responses to SARS-CoV E protein. Microbes Infect 8(9-10):2424-2431
85. Peng H, Yang LT et al (2006b) Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology 351(2):466-475
86. Perlman S, Dandekar AA (2005) Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol 5(12):917-927
87. Poccia F, Agrati C et al (2006) Anti-severe acute respiratory syndrome coronavirus immune responses: the role played by V gamma 9V delta 2 T cells. J Infect Dis 193(9):1244-1249
88. Poutanen SM, Low DE et al (2003) Identification of severe acute respiratory syndrome in Canada. N Engl J Med 348(20):1995-2005
89. Roberts A, Thomas WD et al (2006) Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J Infect Dis 193(5):685-692
90. Roberts A, Lamirande EW et al (2008) Animal models and vaccines for SARS-CoV infection. Virus Res 133(1):20-32
91. Schneider-Schaulies S, Niewiesk S et al (2001) Measles virus induced immunosuppression: targets and effector mechanisms. Curr Mol Med 1(2):163-181
92. See RH, Zakhartchouk AN et al (2006) Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol 87(Pt 3):641-650
93. Sheahan T, Morrison TE et al (2008) MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog 4(12):e1000240
94. Shi Z, Hu Z (2008) A review of studies on animal reservoirs of the SARS coronavirus. Virus Res 133(1):74-87
95. Simmons G, Gosalia DN et al (2005) Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA 102(33):11876-11881
96. Siu KL, Kok KH et al (2009) Severe acute respiratory syndrome Coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3{middle dot}TANK{middle dot}TBK1/IKK{epsilon} complex. J Biol Chem 284(24):16202-16209
97. Soo YO, Cheng Y et al (2004) Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 10(7):676-678
98. Spiegel M, Pichlmair A et al (2005) Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3. J Virol 79(4):2079-2086
99. Stadler K, Masignani V et al (2003) SARS-beginning to understand a new virus. Nat Rev Microbiol 1(3):209-218
100. Stadler K, Roberts A et al (2005) SARS vaccine protective in mice. Emerg Infect Dis 11(8):1312-1314
101. Stockman LJ, Bellamy R et al (2006) SARS: systematic review of treatment effects. PLoS Med 3(9):e343
102. Subbarao K, McAuliffe J et al (2004) Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 78(7):3572-3577
103. Sui J, Li W et al (2004) Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA 101(8):2536-2541
104. Tan YJ, Fielding BC et al (2004) Overexpression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway. J Virol 78(24):14043-14047
105. Temperton NJ, Chan PK et al (2005) Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis 11(3):411-416
106. ter Meulen J, Bakker AB et al (2004) Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363(9427):2139-2141
107. To KF, Tong JH et al (2004) Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in-situ hybridization study of fatal cases. J Pathol 202(2):157-163
108. Traggiai E, Becker S et al (2004) An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10(8):871-875
109. Tripet B, Howard MW et al (2004) Structural characterization of the SARS-coronavirus spike S fusion protein core. J Biol Chem 279(20):20836-20849
110. Tsang KW, Ho PL et al (2003) A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348(20):1977-1985
111. Tseng CT, Perrone LA et al (2005) Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection. J Immunol 174(12):7977-7985
112. Vennema H, de Groot RJ et al (1990) Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol 64(3):1407-1409
113. Weingartl H, Czub M et al (2004) Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 78(22):12672-12676
114. Wong RS, Wu A et al (2003) Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ 326(7403):1358-1362
115. Wong CK, Lam CW et al (2004) Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 136(1):95-103
116. Yang ZY, Huang Y et al (2004a) pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol 78(11):5642-5650
117. Yang ZY, Kong WP et al (2004b) A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428(6982):561-564
118. Yang Y, Xiong Z et al (2005a) Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors. Biochem J 392(Pt 1):135-143
119. Yang ZY, Werner HC et al (2005b) Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci USA 102(3):797-801
120. Yang LT, Peng H et al (2006) Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. Clin Immunol 120(2):171-178
121. Yang L, Peng H et al (2007) Persistent memory CD4+ and CD8+ T-cell responses in recovered severe acute respiratory syndrome (SARS) patients to SARS coronavirus M antigen. J Gen Virol 88(Pt 10):2740-2748
122. Yen YT, Liao F et al (2006) Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J Virol 80(6):2684-2693
123. Yilla M, Harcourt BH et al (2005) SARS-coronavirus replication in human peripheral monocytes/macrophages. Virus Res 107(1):93-101
124. Yoshikawa T, Hill T et al (2009) Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J Virol 83(7):3039-3048
125. Zhang Y, Li J et al (2004) Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun 72(8):4410-4415
126. Zhang Z, Xie YW et al (2005) Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma. Transfusion 45(7):1160-1164
127. Zhao GP (2007) SARS molecular epidemiology: a Chinese fairy tale of controlling an emerging zoonotic disease in the genomics era. Philos Trans R Soc Lond B Biol Sci 362(1482):1063-1081
128. Zhao X, Nicholls JM et al (2008) Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-beta signaling. J Biol Chem 283(6):3272-3280
129. Zhou M, Xu D et al (2006) Screening and identification of severe acute respiratory syndrome-associated coronavirus-specific CTL epitopes. J Immunol 177(4):2138-2145
130. Zhu Z, Chakraborti S et al (2007) Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci USA 104(29):12123-12128
131. Zinkernagel RM, Hengartner H (2004) On immunity against infections and vaccines: credo 2004. Scand J Immunol 60(1-2):9-13